This study looks at how well a medicine called remibrutinib works for people with food allergies to peanuts, milk, or eggs. Food allergies can cause the body to react badly when eating certain foods. The study lasts for 52 weeks (about a year) and includes two periods: a double-blind period where neither the doctor nor the participant knows if they're getting remibrutinib or a placebo (a fake treatment), and an open-label period where everyone knows they're getting remibrutinib.

Participants must be between 12 and 65 years old, have a positive test for the food allergy, and be willing to continue avoiding the foods they are allergic to during the study. They must not have used remibrutinib or similar medicines before or be allergic to any study-related materials.

• The study runs for 52 weeks, with different treatment stages.
• Participants may continue to get the medicine after the main study if eligible.
• There is a 4-week follow-up period for those not joining the extended study.